Your browser doesn't support javascript.
Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
Kasztelewicz, Beata; Janiszewska, Katarzyna; Burzynska, Julia; Szydlowska, Emilia; Migdal, Marek; Dzierzanowska-Fangrat, Katarzyna.
  • Kasztelewicz B; Department of Clinical Microbiology and Immunology, The Children's Memorial Health Institute, Warsaw, Poland.
  • Janiszewska K; Department of Clinical Microbiology and Immunology, The Children's Memorial Health Institute, Warsaw, Poland.
  • Burzynska J; Department of Clinical Microbiology and Immunology, The Children's Memorial Health Institute, Warsaw, Poland.
  • Szydlowska E; Department of Clinical Microbiology and Immunology, The Children's Memorial Health Institute, Warsaw, Poland.
  • Migdal M; Department of Anaesthesiology and Intensive Care, The Children's Memorial Health Institute, Warsaw, Poland.
  • Dzierzanowska-Fangrat K; Department of Clinical Microbiology and Immunology, The Children's Memorial Health Institute, Warsaw, Poland.
PLoS One ; 16(4): e0249550, 2021.
Article in English | MEDLINE | ID: covidwho-1186604
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Data on the prevalence of the SARS-CoV-2 antibody in healthcare workers (HCWs) is scarce, especially in pediatric settings. The purpose of this study was to evaluate SARS-CoV-2 IgG-positivity among HCWs of a tertiary pediatric hospital. In addition, follow-up of the serological response in the subgroup of seropositive HCWs was analysed, to gain some insight on the persistence of IgG antibodies to SARS-CoV-2. We performed a retrospective analysis of voluntary SARS-CoV-2 IgG testing, which was made available free of charge to HCWs of the Children's Memorial Health Institute in Warsaw (Poland). Plasma samples were collected between July 1 and August 9, 2020, and tested using the Abbott SARS-CoV-2 IgG assay. Of 2,282 eligible participants, 1,879 (82.3%) HCWs volunteered to undergo testing. Sixteen HCWs tested positive for SARS-CoV-2 IgG, corresponding to a seroprevalence of 0.85%. Among seropositive HCWs, three HCWs had confirmed COVID-19. Nine (56.3%) of the seropositive HCWs reported neither symptoms nor unprotected contact with confirmed SARS-CoV-2 cases in the previous months. A decline in the IgG index was observed at a median time of 86.5 days (range84‒128 days) after symptom onset or RT-PCR testing. Further studies are necessary to elucidate the duration of persistence of anti-SARS-CoV-2 antibodies, as well as the correlation between seropositivity and protective immunity against reinfection. Regardless of the persistence of antibodies and their protective properties, such low prevalence indicates that this population is vulnerable to a second wave of the COVID-19 pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Health Personnel / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0249550

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Health Personnel / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0249550